Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Adv Sci (Weinh). 2024 Jul;11(28):e2401797. doi: 10.1002/advs.202401797. Epub 2024 May 10.
Gene knock-in refers to the insertion of exogenous functional genes into a target genome to achieve continuous expression. Currently, most knock-in tools are based on site-directed nucleases, which can induce double-strand breaks (DSBs) at the target, following which the designed donors carrying functional genes can be inserted via the endogenous gene repair pathway. The size of donor genes is limited by the characteristics of gene repair, and the DSBs induce risks like genotoxicity. New generation tools, such as prime editing, transposase, and integrase, can insert larger gene fragments while minimizing or eliminating the risk of DSBs, opening new avenues in the development of animal models and gene therapy. However, the elimination of off-target events and the production of delivery carriers with precise requirements remain challenging, restricting the application of the current knock-in treatments to mainly in vitro settings. Here, a comprehensive review of the knock-in tools that do not/minimally rely on DSBs and use other mechanisms is provided. Moreover, the challenges and recent advances of in vivo knock-in treatments in terms of the therapeutic process is discussed. Collectively, the new generation of DSBs-minimizing and large-fragment knock-in tools has revolutionized the field of gene editing, from basic research to clinical treatment.
基因敲入是指将外源功能基因插入靶基因组中以实现持续表达。目前,大多数敲入工具都是基于靶向核酸酶,它可以在靶标处诱导双链断裂(DSB),随后携带功能基因的设计供体可以通过内源性基因修复途径插入。供体基因的大小受基因修复特性的限制,而 DSB 会引起遗传毒性等风险。新一代工具,如 Prime 编辑、转座酶和整合酶,可以在最小化或消除 DSB 风险的同时插入更大的基因片段,为动物模型和基因治疗的发展开辟了新途径。然而,消除脱靶事件和生产具有精确要求的递送载体仍然具有挑战性,这限制了当前的敲入治疗主要应用于体外环境。本文全面综述了不/最小程度依赖 DSB 并利用其他机制的敲入工具。此外,还讨论了体内敲入治疗在治疗过程方面的挑战和最新进展。总之,新一代的 DSB 最小化和大片段敲入工具已经彻底改变了基因编辑领域,从基础研究到临床治疗。